Previous Article | Next Article 
Infection and Immunity, June 2001, p. 3562-3568, Vol. 69, No. 6
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.3562-3568.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Mycobacterium bovis BCG recA
Deletion Mutant Shows Increased Susceptibility to DNA-Damaging Agents
but Wild-Type Survival in a Mouse Infection Model
Peter
Sander,1,2,*
K. G.
Papavinasasundaram,2
Thomas
Dick,3
Evangelos
Stavropoulos,2
Kerstin
Ellrott,1
Burkhard
Springer,1
M. Joseph
Colston,2 and
Erik C.
Böttger1,4
Institut für Medizinische Mikrobiologie, Medizinische
Hochschule Hannover, 30625 Hannover, Germany1;
National Institute for Medical Research, Mill Hill, London NW7
1AA, United Kingdom2; Institute of
Molecular and Cell Biology, Singapore 117609, Republic of
Singapore3; and Institut für
Medizinische Mikrobiologie, Universität Zürich, 8028 Zürich, Switzerland4
Received 20 October 2000/Returned for modification 28 December
2000/Accepted 26 February 2001
 |
ABSTRACT |
Pathogenic microorganisms possess antioxidant defense mechanisms
for protection from reactive oxygen metabolites which are generated
during the respiratory burst of phagocytic cells. These defense
mechanisms include enzymes such as catalase, which detoxifies reactive
oxygen species, and DNA repair systems, which repair damage resulting
from oxidative stress. To (i) determine the relative importance of the
DNA repair system when oxidative stress is encountered by the
Mycobacterium tuberculosis complex during infection of the host and to (ii) provide improved mycobacterial hosts as live carriers to express foreign antigens, the recA locus was
inactivated by allelic exchange in Mycobacterium bovis
BCG. The recA mutants are sensitive to
DNA-damaging agents and show increased susceptibility to metronidazole,
the first lead compound active against the dormant M.
tuberculosis complex. Surprisingly, the recA
genotype does not affect the in vitro dormancy response, nor
does the defect in the DNA repair system lead to attenuation as
determined in a mouse infection model. The recA mutants
will be a valuable tool for further development of BCG as an antigen
delivery system to express foreign antigens and as a source of a
genetically stable vaccine against tuberculosis.
 |
INTRODUCTION |
Mycobacterium bovis BCG
is a live vaccine against tuberculosis that has been administered to
more than one billion people worldwide (6). In addition,
BCG is used as a nonspecific immunotherapeutic agent in cancer
treatment (38, 41). Although BCG shows a great deal of
geographic variability in its ability to protect against lung
tuberculosis (17), in most trials, BCG revealed
significant protection against early childhood tuberculosis and
disseminated manifestations of the disease (6). M. bovis BCG has been suggested as an ideal delivery system for
expression of foreign antigens due to the long persistence of BCG in
the immunized host (1, 21, 23, 33, 48, 58).
Despite its widespread use BCG is known to cause severe infections in
immunocompromised individuals (24, 45, 46, 52), indicating
that this organism is endowed with residual virulence properties which
may be manifested in the absence of an effective immune response. It is
thought that the ability of BCG to survive for prolonged periods
without causing progressive infection in immunocompetent individuals is
an important component of its protective properties (2).
BCG is known to have undergone significant genetic rearrangements, and
recent evidence suggests that major recombinational events resulting in
duplication of large segments of the chromosome have occurred and are
still occurring (3, 16). Thus, if BCG is to be retained as
a vaccine in its own right, developed as a carrier for generating novel
vaccines and still used as an immunotherapeutic agent, it is essential
that a more genetically stable strain be developed.
Phagocytic cells are able to generate superoxide, hydrogen peroxide,
and other reactive oxygen metabolites which are capable of damaging
microbial DNA, proteins, and membranes (22).
Microorganisms possess multiple defenses against oxidative stress
including enzymes such as catalase and DNA repair systems, which repair
damage resulting from oxidative stress (47). The enzyme
catalase catalyzes the decomposition of toxic hydrogen peroxide
to water and oxygen; a correlation between catalase activity and
virulence has been observed for the Mycobacterium
tuberculosis complex (7, 28).
RecA is the regulator of the error-prone DNA repair mechanism (SOS
response) and a key element of homologous recombination (53). The RecA of the M. tuberculosis complex
has an unusual structure, in that it contains a protein-splicing
element, termed intein (10). Difficulties in achieving
homologous recombination in the M. tuberculosis complex
have, at least partially, been attributed to this unusual structure
(34). However, recent data suggest that the M. tuberculosis RecA intein does not interfere with RecA function
(18, 39). DNA repair mechanisms in general and RecA
function in particular have been shown to be essential for the survival
of intracellular pathogens by repairing DNA damage resulting from
oxidative stress, e.g., in Salmonella enterica serovar
Typhimurium (5).
In general, live vaccine strains should possess a
RecA
phenotype. (i) Mutant recA
strains are genetically more stable than their
recA+ counterparts, reducing concerns about
major genetic changes resulting in an altered phenotype
(25). (ii) RecA acts as an inducible positive regulator of
interspecies gene exchange in bacteria (31, 32); a mutant
recA allele averts reversion of virulence attenuation by
interspecies gene transfer (35). (iii) Mutant
recA strains are more sensitive to UV irradiation and other
DNA-damaging agents and thus show reduced persistence in the
environment (35). (iv) Expression of foreign antigens is
more stable in a mutant recA background (43).
However, if the lack of a functional RecA results in a reduced ability
to survive in the host, the immunogenicity of, for example, BCG could
be compromised.
To generate M. bovis BCG recA knockout mutants,
we wanted to adapt a technique previously established successfully for
Mycobacterium smegmatis (44). This technique is
based on the dominant-negative selectable marker
rpsL+, which confers streptomycin
sensitivity to a streptomycin-resistant host, allowing the isolation of
allelic replacement mutants from single-crossover recombinants. The
successful adoption of this strategy would complement other techniques
to generate targeted mutants in the M. tuberculosis complex
which make use of a combined counterselection provided by
sacB and a thermosensitive origin of plasmid replication
(42). Here we describe the generation of an M. bovis BCG recA knockout mutant by use of
rpsL as a counterselectable marker and report on the
characterization of the mutant with respect to DNA repair, in vitro
induced dormancy, and survival in vivo.
 |
MATERIALS AND METHODS |
DNA manipulations and isolation of plasmids.
Standard
techniques were used for DNA manipulation. All initial cloning
procedures were performed with E. coli XL1-Blue MRF. Plasmids were prepared with a Qiagen plasmid preparation kit according to the manufacturer's recommendations. Plasmid DNA was dissolved in
Tris-EDTA buffer in concentrations of 500 to 1,000 ng/µl.
Generation of suicide vectors.
For the generation of
suicide vector precA::aph-rpsL, the following cloning
steps were performed. A 5.2-kb ApaI fragment from plasmid
pEJ126 (10) containing M. tuberculosis recA was
subcloned into the PstI site of plasmid pBluescript KSII(
)
(Stratagene), resulting in plasmid pBluescript-recA. From this vector,
a 1.3-kbp internal PstI fragment was replaced by a 1.3-kbp
aph cassette isolated as a PstI fragment from
plasmid pUC4K (Pharmacia), resulting in plasmid precA::aph. A
fragment comprising the inactivated recA was removed by
digestion with EcoRV and SpeI and cloned into
ptrpA-1-rpsL previously digested with SacI, blunt ended, and
subsequently digested with SpeI (44), resulting
in suicide vector precA::aph-rpsL. The cloning procedures
were confirmed by DNA sequencing.
Cultivation of mycobacteria.
When cultivated on solid
medium, M. bovis BCG was grown on Middlebrook 7H10 agar
supplemented with oleic acid-albumin-dextrose (OADC) (Difco) for 3 weeks at 37°C. Tween 80 was added to liquid broth 7H9-OADC to avoid
clumping; incubation was performed in a roller bottle for 10 to 20 days. Antibiotics were added to the following concentrations:
kanamycin, 25 µg/ml; streptomycin, 25 µg/ml.
Southern blot analyses.
For Southern blot analyses, 200 ng
of genomic DNA was digested with an appropriate restriction enzyme,
separated on an agarose gel, and treated according to standard
protocols. DNA was transferred to a Hybond-N membrane (Amersham) and
cross-linked by UV irradiation. DNA was hybridized to a recA
probe (a 1.6-kbp ApaI-PstI fragment from
pBluescript-recA) labeled with digoxigenin according to the manufacturer's instructions (Boehringer GmbH, Mannheim, Germany), washed under stringent conditions, and developed with an antibody directed against digoxigenin coupled with horseradish peroxidase.
Western blot analyses.
M. bovis BCG strains were
grown in 100 ml of Dubos broth and induced with ofloxacin (1 µg/ml)
for 24 h, and cell extracts were prepared as described previously
(39). Cell extracts corresponding to 30 µg of protein
were separated by sodium dodecyl sulfate-polyacrylamide electrophoresis
through a 10% polyacrylamide gel, and the proteins were electroblotted
onto a polyvinylidene difluoride membrane (Immobilon-P; Millipore). The
membrane was blocked with 10% nonfat milk in TTBS (20 mM Tris [pH
7.5)], 0.5 M NaCl buffer containing 0.1% Tween 20) and incubated with
a 1:1,000 dilution of a mouse antiserum raised against the purified
M. tuberculosis RecA protein. A mouse antibody conjugated to
horseradish peroxidase (Dako) was used as secondary antibody. After
being washed with TTBS, the blot was developed with diaminobenzidine
reagent solution as described previously (11).
Generation of M. bovis BCG SMR1.
To generate
streptomycin-resistant mutants, M. bovis BCG (strain
Pasteur) was spread on 7H10-OADC agar containing streptomycin (20 µg/ml). After 4 weeks of incubation, single colonies were picked. The
genotypes of the streptomycin-resistant strains were determined by
PCR-mediated amplification of rrs and rpsL. The sequencing of rrs and rpsL PCR products revealed
a single A
G transition in rpsL codon 88 conferring an
amino acid change from lysine to arginine.
Transformation of M. bovis BCG SMR1.
M.
bovis BCG SMR1 was grown in a 2-liter roller bottle containing 400 ml of 7H9-OADC-Tween until an optical density (OD) of 0.6 was
achieved. One day before harvesting the cells, glycine was added to a
final concentration of 1.5% (vol/vol), and cells were incubated for an
additional 24 h. All the following steps were performed at room
temperature. Cells were harvested by centrifugation, washed several
times with 10% glycerol, and finally resuspended in a volume of 5 ml.
For electroporation, 400 µl of competent cells was mixed with 1 µg
of supercoiled plasmid DNA and electroporated (Gene pulser II; Bio-Rad)
with the following settings: 2.5 kV, 1,000 ohms, 25 µF. After
electroporation cells were resuspended in 4 ml of 7H9-OADC-Tween and
incubated for 20 h with vigorous shaking at 37°C. Following
incubation, appropriate dilutions were plated on selective agar. Single
colonies were picked, restreaked, and grown in liquid broth.
Transformants which had undergone a homologous single crossover were
grown in liquid broth until an optical density of approximately 0.5 was
achieved. Afterwards, appropriate dilutions were spread on plates
containing either kanamycin or kanamycin plus streptomycin. After 4 weeks of incubation, the efficiency of counterselection was determined
by dividing the number of colonies obtained on plates containing
kanamycin plus streptomycin by the number of colonies obtained on kanamycin.
EMS and MMS assay.
7H9-OADC medium containing ethylmethane
sulfonic ethyl ester (EMS) or ethylmethane sulfonic methyl ester (MMS)
was inoculated with a 1/50 volume of a freshly grown culture (OD, 0.5).
After 6 days of incubation, the OD was determined. 7H9-OADC medium
without alkylating chemicals served as a control.
UV irradiation assay.
For the UV irradiation assay, 100-µl
aliquots of a freshly grown culture (OD at 600 nm
[OD600] = 0.1) were placed in an inverted lid
of a 24-well culture plate and put under a standard germicidal UV lamp
(distance, 20 cm). Cells were irradiated for different time periods,
and samples were removed and plated. Mean values and standard
deviations from three independent experiments are shown. Appropriate
dilutions of each culture were plated out in duplicate.
In vitro induced dormancy.
Experiments were performed as
described previously using an in vitro dormancy model
(29). Briefly, screw-cap test tubes (20 by 125 mm) with a
total fluid capacity of 25.5 ml were used. An early-log-phase culture
was diluted to an OD600 of 0.005 in a total
volume of 17 ml of Dubos broth (Difco). Solid caps with latex liners
were tightly screwed down (limited oxygen supply), and the cultures
were gently stirred at 170 rpm for 20 days. Self-generated oxygen
depletion was monitored via the decolorization of the oxygen indicator
dye methylene blue. The growth of cultures was monitored by determining
OD600; viable counts were determined by plating appropriate dilutions on Dubos oleic acid-albumin-agar (Difco). In some
cases, metronidazole was added at a concentration of 10 µg/ml.
Mean values and standard deviations were determined from three
independent experiments. Each experiment was carried out with duplicate
cultures. Appropriate dilutions of each culture were plated out in triplicate.
Infections.
BALB/c and nude mice (6 to 8 weeks old) were
obtained from the breeding facility at the National Institute for
Medical Research (Mill Hill, United Kingdom). M. bovis BCG
strains were grown in Dubos broth. Logarithmically growing cultures
were diluted in saline to an OD of 0.8; 0.2 ml (approximately
106 CFU) was injected into the tail vein. Mice
were sacrificed according to ethical guidelines at various times
(three mice per BCG strain for each time point), and the spleens and
lungs were removed, weighed, and homogenized. The suspensions were
serially diluted in saline and then plated on 7H10 agar supplemented
with OADC. The plates were incubated for 3 weeks. The results were
calculated and expressed as CFU per organ.
 |
RESULTS |
Generation of M. bovis BCG recA
Strain M. bovis BCG SMR1 (for a list of strains and
plasmids, see Table 1) is a
streptomycin-resistant derivative of M. bovis BCG; this
strain has a mutation in rpsL codon 88 (Lys
Arg), a
mutation known to confer a streptomycin-resistant phenotype.
For generation of recA knockout mutants, M. bovis
BCG SMR1 was transformed with suicide vector precA::aph-rpsL.
This vector carries an M. tuberculosis recA fragment; part
of the coding region and part of the intein coding region of this
fragment have been replaced by a kanamycin resistance cassette.
The wild-type rpsL flanking the inactivated target gene
facilitates isolation of allelic replacement mutants (44).
Transformants were selected on medium containing kanamycin (efficiency
in the range of 10 to 50 transformants per µg of plasmid DNA compared
to 2 × 104 transformants per µg of
plasmid DNA when using plasmid pMV361 as a control).
Transformants obtained with plasmid precA::aph-rpsL were
chosen at random for further investigations.
Genetic analysis of transformants and counterselection.
Nine
of 11 kanamycin-resistant (KanR) clones investigated contained the
aph cassette, indicating that these colonies arose from
transformation with the suicide vector rather than representing spontaneous KanR mutants (data not shown). Genomic DNA was isolated and
investigated by Southern blot analyses using a recA fragment as the probe (Fig. 1). Two of the nine
transformants revealed a pattern indicative of a 5' single crossover at
the recA locus (a 2.6-kbp fragment and a 4.9-kbp fragment;
the wild type shows a 2-kbp fragment) and were subjected to
counterselection on medium containing kanamycin plus streptomycin.
Transformants resistant to kanamycin plus streptomycin
(frequency, 10
4 to 10
5)
were screened by PCR for the absence of the deleted recA
intein coding sequence (7 of 40 transformants were investigated; data not shown). recA deletion was confirmed by Southern blot
analyses. Following digestion with SmaI the kanamycin- and
streptomycin-resistant transformants revealed a single 2.6-kbp
fragment (Fig. 1), indicating a second crossover event, resulting in
loss of the functional recA copy. For further
investigations, one of the recA mutants was chosen.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Southern blot analysis of the recA
locus. Lane 1, parental M. bovis BCG; lane 2, single-crossover transformant obtained by transformation with plasmid
precA::aph-rpsL; lanes 3 to 5, recA
(recA::aph) knockout mutants obtained after counterselection
of a single-crossover transformant on medium containing kanamycin plus
streptomycin. Approximately 200 ng of genomic DNA was digested with
SmaI and hybridized to a recA probe. (B)
Schematic drawing of the BCG recA locus: the wild-type
locus is shown along with the vector used for inactivation, a 5'
single-crossover transformant, and a knockout mutant. S,
SmaI recognition site.
|
|
Western blot analyses.
Western blot analyses using an
antiserum raised against M. tuberculosis RecA was performed
with the parental strain, a single-crossover transformant, and the
corresponding knockout mutant (Fig. 2). A
single band with a molecular mass of approximately 40 kDa corresponding to the mature, spliced form of M. tuberculosis RecA was
observed in extracts of both the parental strain and the
single-crossover transformant but not in the recA mutant,
indicating the absence of the RecA protein and thus confirming the data
obtained by Southern blot analysis. A faint band with a mass of
approximately 20 kDa possibly corresponding to a truncated N-terminal
RecA fragment was detected in recA single-crossover
transformants and in the recA knockout mutant.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 2.
Western blot analysis of RecA. Lane 1, parental
M. bovis BCG; lane 2, single-crossover transformant;
lane 3, recA knockout mutant. Approximately 30 µg of
protein was separated on a polyacrylamide gel, transferred to a
polyvinylidene difluoride membrane, and probed with an antibody raised
against M. tuberculosis RecA.
|
|
In vitro characterization of M. bovis BCG
recA. (i) M. bovis BCG
recA mutant strains are sensitive to alkylating
agents.
One of the most noticeable phenotypes of recA
mutant strains is their increased sensitivity to DNA-damaging agents
(26). To investigate the physiological effects of
recA inactivation, several tests with different DNA-damaging
agents were performed. The ability of recA+
and recA mutant strains to grow in the presence of EMS or
MMS was determined in liquid broth (Table
2).
The presence of 0.05% EMS only slightly inhibited growth of the
recA+ strain. In contrast, growth of the
recA mutant strain was reduced 10-fold compared to that of
the control. Similar results were obtained with MMS. At a concentration
of 0.006% MMS growth of the recA+ strain
was not significantly affected, whereas growth of the recA
mutant strain was inhibited by approximately 90%. In the absence of
DNA-alkylating agents the growth rates of the
recA+ and the recA mutant
strains were indistinguishable. The single-crossover transformant
essentially behaved like the recA+ strain
in the presence of DNA-damaging agents.
(ii) M. bovis BCG recA mutants are
sensitive to UV irradiation.
Irradiation with UV light is
frequently used to compare the levels of effectiveness of DNA repair
mechanisms. Inactivation of recA rendered BCG sensitive to
UV irradiation: the recA strain exhibited a
10,000-fold-decreased viability after 30 s of irradiation compared
with a 25-fold decrease for the recA+
strain (Fig. 3). The survival rate
decreased dramatically at higher irradiation dosages; very few mutant
survivors were detected after 60 s of irradiation (<0.0001%),
compared to about a 0.01% survival rate for the parental strain. These
results support previous observations that, despite the presence of an
intein, M. bovis BCG RecA is functionally expressed
and promotes DNA repair mechanisms in mycobacteria (18,
40).

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 3.
Survival after UV irradiation. Parental M.
bovis BCG ( ), a recA single-crossover
transformant ( ), and a recA knockout mutant ( )
were irradiated with UV light for the indicated times. Following
irradiation, the numbers of viable cells were determined by plating.
|
|
(iii) In vitro induced dormancy and metronidazole resistance.
The obligate aerobe M. tuberculosis complex can enter an
anaerobic dormant state in which it survives for extended periods of
time (54). To determine whether recA is
involved in the dormancy response, we investigated
recA+ and recA mutant strains
with respect to their abilities to survive in an in vitro dormancy
model (57). Mycobacteria were grown in sealed and stirred
tubes to achieve self-generated oxygen depletion, a signal which
triggers entry into the dormant state. Growth of the cultures was
monitored by measuring the OD; the number of cells surviving oxygen
depletion was determined by plating. Self-generated oxygen depletion
was judged by fading or decolorization of the indicator methylene blue.
With respect to OD, recA+ and
recA mutant strains behaved identically (Fig.
4). A plateau was achieved after
approximately 8 days. After day 9 and after day 15, respectively,
fading and decolorization of the oxygen indicator methylene blue were
observed in each of the cultures. After incubation for an additional 5 days, cultures were harvested and the numbers of CFU were determined (Fig. 5). The recA genotype
did not affect the number of viable cells after oxygen depletion,
indicating that RecA does not affect in vitro induced-dormancy
survival.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 4.
Growth under dormancy conditions. Parental M.
bovis BCG ( ) and the recA knockout mutant
( ) were grown under dormancy culture conditions. Growth was
determined by measuring the OD. F and D, fading and complete
decolorization of the methylene blue indicator, respectively.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 5.
Survival under dormancy conditions. Survival of parental
M. bovis BCG and the recA knockout mutant
under dormancy culture conditions was investigated by determining the
numbers of CFU after 20 days of incubation in the presence or absence
of metronidazole (MTZ; 10 µg/ml).
|
|
Metronidazole is the first lead compound active against dormant
M. tuberculosis. Metronidazole does not affect the growth of
aerobically grown cultures but acts exclusively on the anaerobically grown M. tuberculosis complex (56). We next
investigated the effect of metronidazole on the growth of
recA+ and recA mutant M. bovis BCG in the in vitro dormancy model described above. Compared
to recA+ M. bovis BCG, the
recA mutant showed increased susceptibility to
metronidazole, i.e., the number of viable cells was reduced about
20-fold by metronidazole for the recA+
strain, but a 100-fold reduction in the number of viable cells was
observed in the recA mutant (Fig. 5).
Survival of the M. bovis BCG recA
mutant in mice.
DNA repair mechanisms in general and RecA in
particular are important virulence factors for the survival of
intracellular pathogens, such as Salmonella
(5). Although wild-type M. bovis BCG does not
cause a progressive infection in mice, it does persist in tissue for a
significant period of time. We thus investigated the effect of
recA inactivation on the survival of M. bovis BCG in a high-dose animal infection model. BALB/c mice were infected by
intravenous injection with M. bovis BCG
recA+, the single-crossover transformant,
and the recA mutant strain. After days 1, 28, and 84, organs
(spleen and lung) were removed and homogenized and appropriate
dilutions were plated on 7H10 agar. The plates were incubated for 3 weeks, and the numbers of CFU per organ were calculated. As shown in
Fig. 6, the knockout mutant showed no
difference in the course of infection compared to the wild-type strain,
either in the spleens or in the lungs of infected BALB/c mice. These
data indicate that RecA is not essential for survival in the high-dose
mouse infection model.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 6.
Course of infection in BALB/c mice. Parental M.
bovis BCG ( ), a recA single-crossover
transformant ( ), and a recA knockout mutant ( )
were injected into the tail vein (approximately 106
CFU/animal). The numbers of bacteria in spleens (A) and lungs (B) were
determined at different time points.
|
|
Athymic mice were inoculated to assess the virulence of the
recA mutant in a more progressive infection model. As shown
in Fig. 7, a comparison of the three strains in athymic
mice did not show significant difference in growth in spleens or lungs.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 7.
Course of infection in nude mice. Parental M.
bovis BCG ( ), a recA single-crossover
transformant ( ), and a recA knockout mutant ( )
were injected into the tail vein (approximately 106
CFU/animal). The numbers of bacteria in spleens (A) and lungs (B) were
determined at different time points.
|
|
 |
DISCUSSION |
Infections with M. tuberculosis are a major cause of
human morbidity and mortality. Vaccines are the most cost-effective
intervention to prevent disease, and M. bovis BCG is a
widely used vaccine; it can be given as a single dose at birth and
confers long-lasting immunity. M. bovis BCG not only is used
as vaccine against tuberculosis but also offers great potential for
innovative approaches for development of polyvalent vaccines (1,
33, 48, 58). Genetic stability and in vivo persistence are of
special importance for the use of live vaccines; a mutant BCG which is
rapidly eliminated is unlikely to be an effective vaccine
(2).
RecA is a multifunctional and ubiquitous protein involved both in
general recombination and in DNA repair. Thus, RecA-mediated DNA repair
mechanisms have been shown to be essential for intracellular survival
and persistence (5), while simultaneously RecA-dependent recombination mediates genetic rearrangements resulting in increased genetic instability (25). As an inducer of the SOS
response RecA regulates at least 20 genes, most of which are usually
suppressed by LexA (36); mycobacteria possess the key
elements of a functional SOS system (13, 37).
Investigations of M. tuberculosis RecA so far have been
performed in vitro, with Escherichia coli and M. smegmatis (10, 11, 12, 18, 27, 40, 51). These
investigations demonstrated that the mature RecA is able to promote DNA
repair mechanisms and homologous recombination (18, 40).
However, as no isogenic M. tuberculosis complex mutants were
available, the possibility that a homologous gene, e.g.,
radA (Rv3585) (8), could compensate for RecA
function could not be excluded. The results presented here show that
BCG recA mutants are sensitive to DNA-damaging agents (DNA
alkylation and UV irradiation) and thus have an in vitro phenotype
similar to those of recA mutants of other species (36). These investigations suggest that M. bovis BCG has a nonredundant recA gene, which is
essential to promote DNA repair mechanisms.
M. bovis BCG and M. tuberculosis are able to
enter a dormant state (29). This response is triggered by
slow self-generated depletion of oxygen (54). Entry into
the dormant state is an adaptive process, as sudden oxygen depletion
results in cell death (55). Experiments in an in vitro
dormancy model were performed to investigate whether RecA is involved
in dormancy survival. As the numbers of viable bacterial cells after
oxygen depletion were essentially identical for the
recA+ and recA mutant strains,
RecA does not appear to play an essential role in entry, survival, or
exit from the dormant state.
Originally developed as an antiparasitic agent, metronidazole has been
recognized as an effective drug for treatment of infections with
anaerobic bacteria. Metronidazole is also active against M. tuberculosis and M. bovis BCG when grown under
anaerobic conditions (29, 56). Our investigations in the
in vitro dormancy model demonstrated that M. bovis BCG
recA knockout mutants show increased susceptibility to
metronidazole. These results support previous findings that
metronidazole acts by damaging DNA after reduction to form a toxic
metabolite (15).
Numerous reports have demonstrated that recA represents an
important virulence factor: RecA is involved in stress survival (14), mediates aerotolerance in microaerophilic bacteria
(9), induces production of colicins, pyocins
(36), and extracellular degradative enzymes
(30), and mediates amplification of toxin genes
(19). Most notably, Salmonella recA mutant
strains are highly attenuated, both in cultured macrophage cells
(4) and in a mouse infection model (5). This
effect has been attributed to the DNA-damaging effect of the oxidative
burst and the reduced ability of the mutants to perform DNA repair
(47). However, a recA mutation does not
necessarily affect bacterial virulence, as demonstrated, e.g., for
Campylobacter jejuni (20),
Corynebacterium pseudotuberculosis (43),
Brucella abortus (50), and some Vibrio cholerae strains (49). It was thus of interest to
investigate the contribution of RecA to the survival of M. bovis BCG in mice. The results indicate that RecA does not
contribute to the establishment and maintenance of infection. This is
an important finding since persistence of BCG following vaccination is
thought to be a significant contributory factor to its immunogenicity;
a mutant BCG which is rapidly eliminated is unlikely to be an effective vaccine.
In analogy to M. tuberculosis (3, 16)
differences between strains of M. bovis BCG can be
attributed to RecA-dependent genetic rearrangements. The BCG
recA mutant constructed in this study is deficient in the
major recombination pathway but is not affected in its in vivo
survival. Due to the increased genetic stability of recA
mutants, this strain is of interest as a tuberculosis vaccine and for
further development of M. bovis BCG as an antigen delivery
system for expression of foreign antigens.
The BCG mutant was generated by adapting an rpsL-based
strategy which has previously been used to generate allelic exchange mutants in M. smegmatis (44). As transformation
efficiencies are a critical issue, the original strategy has been
modified to a two-step allelic exchange procedure incorporating
successive steps of positive and negative selection. The procedure
described is a valuable alternative to strategies which use
sacB and thermosensitive vectors for the generation of
allelic exchange mutants in mycobacteria (42).
 |
ACKNOWLEDGMENTS |
This work was supported in part by grants from the Deutsche
Forschungsgemeinschaft Schwerpunktprogramm "Ökologie
bakterieller Krankheitserreger," BO 820/11-2 and BO 820/13-1, and
the European Community, CT-1999-01093. T.D. was supported by the
Institute of Molecular and Cell Biology (IMCB).
We thank K. Stover for plasmid pMV361 and A. Toh for help with the in
vitro dormancy experiments.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institut
für Medizinische Mikrobiologie, Medizinische Hochschule Hannover,
Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Phone: 511-532-4348. Fax:
511-532-4366. E-mail: Sander.peter{at}gmx.de.
Editor:
S. H. E. Kaufmann
 |
REFERENCES |
| 1.
|
Aldovini, A., and R. A. Young.
1991.
Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines.
Nature
351:479-482[CrossRef][Medline].
|
| 2.
|
Bloom, B. R., and P. E. M. Fine.
1994.
The BCG experience: implications for future vaccines against tuberculosis, p. 531-558.
In
B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. ASM Press, Washington, D.C.
|
| 3.
|
Brosch, R.,
W. J. Philipp,
E. Stavropoulos,
M. J. Colston,
S. T. Cole, and S. V. Gordon.
1999.
Genomic analysis reveals variation between Mycobacterium tuberculosis H37Rv and the attenuated M. tuberculosis H37Ra strain.
Infect. Immun.
67:5768-5774[Abstract/Free Full Text].
|
| 4.
|
Buchmeier, N. A.,
C. J. Lipps,
M. Y. H. So, and F. Heffron.
1993.
Recombination-deficient mutants of Salmonella typhimurium are avirulent and sensitive to the oxidative burst of macrophages.
Mol. Microbiol.
7:933-936[Medline].
|
| 5.
|
Buchmeier, N. A.,
S. J. Libby,
Y. Xu,
P. C. Loewen,
J. Switala,
D. G. Guiney, and F. C. Fang.
1995.
DNA repair is more important than catalase for Salmonella virulence in mice.
J. Clin. Investig.
95:1047-1053.
|
| 6.
|
Cohn, D. L.
1997.
Use of bacille Calmette-Guérin vaccination for the prevention of tuberculosis: renewed interest in an old vaccine.
Am. J. Med. Sci.
6:372-376.
|
| 7.
|
Cohn, M. L.,
C. Kovitz,
V. Oda, and G. Middlebrook.
1954.
Studies on isoniazid and tubercle bacilli. II. The growth requirements, catalase activities and pathogenic properties of isoniazid resistant mutants.
Am. Rev. Tuberc.
70:641-664.
|
| 8.
|
Cole, S. T.,
R. Brosch,
J. Parkhill,
T. Garnier,
C. Churcher,
D. Harris,
S. V. Gordon,
K. Eiglmeier,
S. Gas,
C. E. Barry,
F. Tekaia,
K. Badcock,
D. Basham,
D. Brown,
T. Chillingworth,
R. Connor,
R. Davies,
K. Devlin,
T. Feltwell,
S. Gentles,
N. Hamlin,
S. Holroyd,
T. Hornsby,
K. Jagels,
A. Krogh,
J. McLean,
S. Moule,
L. Murphy,
K. Oliver,
O. J. Osborne,
M. A. Quail,
M. A. Rajandream,
J. Rogers,
S. Rutter,
K. Seeger,
J. Skelton,
R. Squares,
S. Squares,
J. E. Sulston,
S. Whithehead, and B. G. Barrell.
1998.
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.
Nature
393:537-544[CrossRef][Medline].
|
| 9.
|
Cooper, A. J.,
A. P. Kalinowski,
N. B. Shoemaker, and A. A. Salyers.
1997.
Construction and characterization of a Bacteroides thetaiotaomicron recA mutant: transfer of Bacteroides integrated conjugative elements is RecA independent.
J. Bacteriol.
179:6221-6227[Abstract/Free Full Text].
|
| 10.
|
Davis, E. O.,
S. G. Sedgwick, and M. J. Colston.
1991.
Novel structure of the recA locus of Mycobacterium tuberculosis implies processing of the gene product.
J. Bacteriol.
173:5653-5662[Abstract/Free Full Text].
|
| 11.
|
Davis, E. O.,
P. J. Jenner,
P. C. Brooks,
M. J. Colston, and S. G. Sedgwick.
1992.
Protein splicing in the maturation of M. tuberculosis RecA protein: a mechanism for tolerating a novel class of intervening sequence.
Cell
71:201-210[CrossRef][Medline].
|
| 12.
|
Davis, E. O.,
H. S. Thangaraj,
P. C. Brooks, and M. J. Colston.
1994.
Evidence of selection for protein introns in the RecAs of pathogenic mycobacteria.
EMBO J.
13:699-703[Medline].
|
| 13.
|
Durbach, S. I.,
S. J. Andersen, and V. Mizrahi.
1997.
SOS induction in mycobacteria: analysis of the DNA-binding activity of a LexA-like repressor and its role in DNA damage induction of the recA gene from Mycobacterium smegmatis.
Mol. Microbiol.
26:643-653[CrossRef][Medline].
|
| 14.
|
Duwat, P.,
S. D. Ehrlich, and A. Gruss.
1995.
The recA gene of Lactococcus lactis: characterization and involvement in oxidative and thermal stress.
Mol. Microbiol.
17:1121-1131[CrossRef][Medline].
|
| 15.
|
Edwards, D. I.
1979.
Mechanism of antimicrobial action of metronidazole.
J. Antimicrob. Chemother.
5:499-502[Free Full Text].
|
| 16.
|
Fang, Z.,
C. Doig,
D. T. Kenna,
N. Smittipat,
P. Palittapongarnpim,
B. Watt, and K. J. Forbes.
1999.
IS6110-mediated deletions of wild-type chromosomes of Mycobacterium tuberculosis.
J. Bacteriol.
181:1014-1020[Abstract/Free Full Text].
|
| 17.
|
Fine, P. E. M.
1988.
BCG vaccination against tuberculosis and leprosy.
Br. Med. Bull.
44:704-716[Abstract/Free Full Text].
|
| 18.
|
Frischkorn, K.,
P. Sander,
M. Scholz,
K. Teschner,
T. Prammananan, and E. C. Böttger.
1998.
Investigation of mycobacterial recA function: protein introns in the RecA of pathogenic mycobacteria do not affect competency for homologous recombination.
Mol. Microbiol.
29:1203-1214[CrossRef][Medline].
|
| 19.
|
Goldberg, I., and J. J. Mekalanos.
1986.
Effect of recA mutation on cholera toxin gene amplification and deletion events.
J. Bacteriol.
165:723-731[Abstract/Free Full Text].
|
| 20.
|
Guerry, P.,
P. M. Pope,
D. H. Burr,
J. Leifer,
S. W. Joseph, and A. L. Bourgeois.
1994.
Development and characterization of recA mutants of Campylobacter jejuni for inclusion in attenuated vaccines.
Infect. Immun.
62:426-432[Abstract/Free Full Text].
|
| 21.
|
Haeseleer, F.,
J.-F. Pollet,
M. Haumont,
A. Bollen, and P. Jacobs.
1993.
Stable integration and expression of the Plasmodium falciparum circumsporozoite protein coding sequence in mycobacteria.
Mol. Biochem. Parasitol.
57:117-126[CrossRef][Medline].
|
| 22.
|
Hassett, D. J., and M. S. Cohen.
1989.
Bacterial adaptation to oxidative stress: implications for pathogenesis and interaction with phagocytic cells.
FASEB J.
3:2574-2582[Abstract].
|
| 23.
|
Hess, J., and S. H. Kaufmann.
1999.
Live antigen carriers as tools for improved anti-tuberculosis vaccines.
FEMS Immunol. Med. Microbiol
23:165-173[Medline].
|
| 24.
|
Hill, A. V.
1998.
The immunogenetics of human infectious diseases.
Annu. Rev. Immunol.
16:593-617[CrossRef][Medline].
|
| 25.
|
Johnson, B. N.,
A. Weintraub,
A. A. Lindberg, and B. A. D. Stocker.
1992.
Construction of Salmonella strains with both antigen O4 (of group B) and antigen O9 (of group D).
J. Bacteriol.
174:1911-1915[Abstract/Free Full Text].
|
| 26.
|
Kowalczykowski, S. C.,
D. A. Dixon,
A. K. Eggleston,
S. D. Lauder, and W. M. Rehrauer.
1994.
Biochemistry of homologous recombination in Escherichia coli.
Microbiol. Rev.
58:401-465[Abstract/Free Full Text].
|
| 27.
|
Kumar, R. A.,
M. B. Vaze,
N. R. Chandra,
M. Vijayan, and K. Muniyappa.
1996.
Functional characterization of the precursor and spliced forms of RecA protein of Mycobacterium tuberculosis.
Biochemistry
35:1793-1802[CrossRef][Medline].
|
| 28.
|
Li, Z.,
C. Kelley,
F. Collins,
D. Rousse, and S. Morris.
1998.
Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs.
J. Infect. Dis.
177:1030-1035[Medline].
|
| 29.
|
Lim, A.,
M. Eleuterio,
B. Hutter,
B. Murugasu-Oei, and T. Dick.
1999.
Oxygen depletion induced dormancy in Mycobacterium bovis BCG.
J. Bacteriol.
181:2252-2256[Abstract/Free Full Text].
|
| 30.
|
Liu, Y.,
X. Wang,
A. Mukherjee, and A. K. Chatterjee.
1996.
RecA relieves negative autoregulation of rdgA, which specifies a component of the RecA-Rdg regulatory circuit controlling pectin lyase production in Erwinia carotovora ssp. carotovora.
Mol. Microbiol.
22:909-918[CrossRef][Medline].
|
| 31.
|
Martin, B.,
P. Garcia,
M. P. Castanie, and J. P. Claverys.
1995.
The recA gene of Streptococcus pneumoniae is part of a competence-induced operon and controls lysogenic induction.
Mol. Microbiol.
15:367-379[Medline].
|
| 32.
|
Matic, I.,
C. Rayssiguier, and M. Radman.
1995.
Interspecies gene exchange in bacteria: the role of SOS and mismatch repair systems in evolution of species.
Cell
80:507-515[CrossRef][Medline].
|
| 33.
|
Matsuo, K.,
R. Yamaguchi,
A. Yamazaki,
H. Tasaka,
K. Terasaka,
M. Totsuka,
K. Kobayashi,
H. Yukitake, and T. Yamada.
1990.
Establishment of a foreign antigen secretion system in mycobacteria.
Infect. Immun.
58:4049-4054[Abstract/Free Full Text].
|
| 34.
|
McFadden, J.
1996.
Recombination in mycobacteria.
Mol. Microbiol.
21:205-211[CrossRef][Medline].
|
| 35.
|
Mekalanos, J. J.
1994.
Live bacterial vaccines: environmental aspects.
Curr. Opin. Biotechnol.
5:312-319[CrossRef][Medline].
|
| 36.
|
Miller, R. V., and T. A. Kokjohn.
1990.
General microbiology of recA: environmental and evolutionary significance.
Annu. Rev. Microbiol.
44:365-394[Medline].
|
| 37.
|
Movahedzadeh, F.,
M. J. Colston, and E. O. Davis.
1997.
Determination of DNA sequences required for regulated Mycobacterium tuberculosis RecA expression in response to DNA-damaging agents suggests that two modes of regulation exist.
J. Bacteriol.
179:3509-3518[Abstract/Free Full Text].
|
| 38.
|
Nseyo, U. O., and D. L. Lamm.
1997.
Immunotherapy of bladder cancer.
Semin. Surg. Oncol.
13:342-349[CrossRef][Medline].
|
| 39.
|
Papavinasasundaram, K. G.,
F. Movahedzadeh,
J. T. Keer,
N. G. Stoker,
M. J. Colston, and E. O. Davis.
1997.
Mycobacterial recA is cotranscribed with a potential regulatory gene called recX.
Mol. Microbiol
24:141-153[CrossRef][Medline].
|
| 40.
|
Papavinasasundaram, K. G.,
M. J. Colston, and E. O. Davis.
1998.
Construction and complementation of a recA deletion mutant of Mycobacterium smegmatis reveals that the intein in Mycobacterium tuberculosis recA does not affect RecA function.
Mol. Microbiol.
30:525-534[CrossRef][Medline].
|
| 41.
|
Patard, J. J.,
F. Saint,
F. Velotti,
C. C. Abbou, and D. K. Chopin.
1998.
Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review.
Urol. Res.
26:155-159[CrossRef][Medline].
|
| 42.
|
Pelicic, V.,
M. Jackson,
J. M. Reyrat,
W. R. Jacobs,
B. Gicquel, and C. Guilhot.
1997.
Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis.
Proc. Natl. Acad. Sci. USA
94:10955-10960[Abstract/Free Full Text].
|
| 43.
|
Pogson, C. A.,
C. P. Simmons,
R. A. Strugnell, and A. L. M. Hodgson.
1996.
Cloning and manipulation of the Corynebacterium pseudotuberculosis recA gene for live vaccine vector development.
FEMS Microbiol. Lett.
142:139-145[CrossRef][Medline].
|
| 44.
|
Sander, P.,
A. Meier, and E. C. Böttger.
1995.
rpsL+: a dominant selectable marker for gene replacement in mycobacteria.
Mol. Microbiol.
16:991-1000[CrossRef][Medline].
|
| 45.
|
Steg, A.,
C. Leleu,
B. Debre,
L. Boccon-Gibod, and D. Sicard.
1989.
Systemic bacillus Calmette-Guerin infection, "BCGitis," in patients treated by intravesical bacillus Calmette-Guerin therapy for bladder cancer.
Eur. Urol.
16:161-164[Medline].
|
| 46.
|
Stone, M. M.,
A. M. Vannier,
S. K. Storch,
C. Peterson,
A. T. Nitta, and Y. Zhang.
1995.
Brief report: meningitis due to iatrogenic BCG infection in two immunocompromised children.
N. Engl. J. Med.
333:561-563[Free Full Text].
|
| 47.
|
Storz, G.,
L. A. Tartaglia,
S. B. Farr, and B. N. Ames.
1990.
Bacterial defenses against oxidative stress.
Trends Genet.
6:363-368[CrossRef][Medline].
|
| 48.
|
Stover, C. K.,
V. F. de la Cruz,
T. R. Fuerst,
J. E. Burlein,
L. A. Benson,
L. T. Bennett,
G. P. Bansal,
J. F. Young,
M. H. Lee,
G. F. Hatfull,
S. B. Snapper,
R. G. Barletta,
W. R. Jacobs, and B. R. Bloom.
1991.
New use of BCG for recombinant vaccines.
Nature
351:456-460[CrossRef][Medline].
|
| 49.
|
Ströher, W. H.,
A. J. Lech, and P. A. Manning.
1994.
Gene sequence of recA+ and construction of recA mutants of Vibrio cholerae.
Mol. Gen. Genet.
244:295-302[Medline].
|
| 50.
|
Tatum, F. M.,
D. C. Morfitt, and S. M. Halling.
1993.
Construction of a Brucella abortus RecA mutant and its survival in mice.
Microb. Pathog.
14:177-185[CrossRef][Medline].
|
| 51.
|
Vaze, M. B., and K. Muniyappa.
1999.
RecA protein of Mycobacterium tuberculosis possesses pH-dependent homologous DNA pairing and strand exchange activities: implications for allele exchange in mycobacteria.
Biochemistry
38:3175-3186[CrossRef][Medline].
|
| 52.
|
Vesterhus, P.,
S. M. Holland,
T. G. Abrahamsen, and R. Bjerknes.
1998.
Familial disseminated infection due to atypical mycobacteria with childhood onset.
Clin. Infect. Dis.
27:822-825[Medline].
|
| 53.
|
Walker, G. C.
1995.
SOS-regulated proteins in translesion DNA synthesis and mutagenesis.
Trends Biol. Sci.
20:416-420.
|
| 54.
|
Wayne, L. G.
1994.
Dormancy of Mycobacterium tuberculosis and latency of disease.
Eur. J. Microbiol. Infect. Dis.
13:908-914.
|
| 55.
|
Wayne, L. G., and G. A. Diaz.
1967.
Autolysis and secondary growth of Mycobacterium tuberculosis in submerged culture.
J. Bacteriol.
93:1374-1381[Abstract/Free Full Text].
|
| 56.
|
Wayne, L. G., and H. A. Sramek.
1994.
Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis.
Antimicrob. Agents Chemother.
38:2054-2058[Abstract/Free Full Text].
|
| 57.
|
Wayne, L. G., and L. G. Hayes.
1996.
An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.
Infect. Immun.
64:2062-2069[Abstract].
|
| 58.
|
Winter, N.,
M. Lagranderie,
J. Rauzier,
J. Timm,
C. Leclerc,
B. Guy,
M. P. Kieny,
M. Gheorghiu, and B. Gicquel.
1991.
Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein.
Gene
109:47-54[CrossRef][Medline].
|
Infection and Immunity, June 2001, p. 3562-3568, Vol. 69, No. 6
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.6.3562-3568.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Stephanou, N. C., Gao, F., Bongiorno, P., Ehrt, S., Schnappinger, D., Shuman, S., Glickman, M. S.
(2007). Mycobacterial Nonhomologous End Joining Mediates Mutagenic Repair of Chromosomal Double-Strand DNA Breaks. J. Bacteriol.
189: 5237-5246
[Abstract]
[Full Text]
-
Warner, D. F., Mizrahi, V.
(2006). Tuberculosis Chemotherapy: the Influence of Bacillary Stress and Damage Response Pathways on Drug Efficacy. Clin. Microbiol. Rev.
19: 558-570
[Abstract]
[Full Text]
-
Huet, G., Daffe, M., Saves, I.
(2005). Identification of the Mycobacterium tuberculosis SUF Machinery as the Exclusive Mycobacterial System of [Fe-S] Cluster Assembly: Evidence for Its Implication in the Pathogen's Survival. J. Bacteriol.
187: 6137-6146
[Abstract]
[Full Text]
-
Darwin, K. H., Nathan, C. F.
(2005). Role for Nucleotide Excision Repair in Virulence of Mycobacterium tuberculosis. Infect. Immun.
73: 4581-4587
[Abstract]
[Full Text]
-
Frota, C. C., Papavinasasundaram, K. G., Davis, E. O., Colston, M. J.
(2004). The AraC Family Transcriptional Regulator Rv1931c Plays a Role in the Virulence of Mycobacterium tuberculosis. Infect. Immun.
72: 5483-5486
[Abstract]
[Full Text]
-
Enanga, B., Ariyanayagam, M. R., Stewart, M. L., Barrett, M. P.
(2003). Activity of Megazol, a Trypanocidal Nitroimidazole, Is Associated with DNA Damage. Antimicrob. Agents Chemother.
47: 3368-3370
[Abstract]
[Full Text]
-
Venkatesh, J., Kumar, P., Krishna, P. S. M., Manjunath, R., Varshney, U.
(2003). Importance of Uracil DNA Glycosylase in Pseudomonas aeruginosa and Mycobacterium smegmatis, G+C-rich Bacteria, in Mutation Prevention, Tolerance to Acidified Nitrite, and Endurance in Mouse Macrophages. J. Biol. Chem.
278: 24350-24358
[Abstract]
[Full Text]
-
Durbach, S. I., Springer, B., Machowski, E. E., North, R. J., Papavinasasundaram, K. G., Colston, M. J., Bottger, E. C., Mizrahi, V.
(2003). DNA Alkylation Damage as a Sensor of Nitrosative Stress in Mycobacterium tuberculosis. Infect. Immun.
71: 997-1000
[Abstract]
[Full Text]
-
Boon, C., Dick, T.
(2002). Mycobacterium bovis BCG Response Regulator Essential for Hypoxic Dormancy. J. Bacteriol.
184: 6760-6767
[Abstract]
[Full Text]